<p>Cartesian Therapeutics（納斯達克股票代碼：RNAC - 獲取免費報告）在週五向投資者發佈的一份報告中，投資分析師 Needham &amp; Company LLC 將其目標價格從 40.00 美元上調至 42.00 美元，Benzinga 報道。該券商目前對該股票給予 “買入” 評級。Needham &amp; Company LLC 的目標價格暗示該公司當前價格有 436.33% 的潛在上漲空間。</p>
<p>獲取 <strong>Cartesian Therapeutics</strong> 的提醒：</p>
<p>其他幾位分析師最近也對該股票發表了看法。BTIG Research 在 11 月 14 日的研究報告中將 Cartesian Therapeutics 的目標價格從 42.00 美元上調至 44.00 美元，並給予該公司 “買入” 評級。華爾街 Zen 在 11 月 8 日的研究報告中將 Cartesian Therapeutics 的評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 12 月 29 日的報告中重申了對 Cartesian Therapeutics 的 “賣出（e+）” 評級。最後，HC Wainwright 在 11 月 19 日的報告中將 Cartesian Therapeutics 的目標價格從 40.00 美元下調至 30.00 美元，並對該股票給予 “買入” 評級。四位投資分析師對該股票給予 “買入” 評級，一位分析師對該公司給予 “賣出” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，平均目標價格為 38.50 美元。</p>
<p><strong>查看我們關於 RNAC 的最新報告</strong></p>
<h2>Cartesian Therapeutics 股票下跌 3.6%</h2>
<p>在週五的午盤交易中，納斯達克：RNAC 的股票下跌 0.29 美元，報 7.83 美元。該公司交易了 42,503 股，而其平均交易量為 145,958 股。該公司的 50 日移動平均價格為 7.38 美元，200 日移動平均價格為 9.58 美元。該公司的市值為 2.0364 億美元，市盈率為-5.07，貝塔值為 0.38。Cartesian Therapeutics 的 12 個月低點為 5.98 美元，12 個月高點為 20.12 美元。</p>
<p>Cartesian Therapeutics（納斯達克股票代碼：RNAC - 獲取免費報告）最後一次公佈季度財報是在 11 月 6 日。該公司報告本季度每股收益為（1.38 美元），低於市場共識預期的（0.81 美元）0.57 美元。該公司本季度的收入為 45 萬美元，而分析師預期為 18 萬美元。分析師預測 Cartesian Therapeutics 在當前年度的每股收益將為 4.56 美元。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席財務官 Blaine Davis 在 1 月 6 日的交易中出售了 10,591 股該公司的股票。股票以平均價格 6.82 美元出售，總價值為 72,230.62 美元。出售後，首席財務官直接持有該公司 121,220 股股票，估值約為 826,720.40 美元。這筆交易代表其持股比例下降了 8.03%。該交易已在證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。60.30% 的股票目前由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一些大型投資者最近調整了對 RNAC 的持股。Rhumbline Advisers 在第一季度將其在 Cartesian Therapeutics 的持股增加了 27.5%。Rhumbline Advisers 目前持有 13,006 股該公司的股票，價值 171,000 美元，此前在上個季度增持了 2,805 股。Miller Financial Services LLC 在第二季度購買了價值約 121,000 美元的 Cartesian Therapeutics 新股份。Virtus Investment Advisers LLC 在第二季度將其在 Cartesian Therapeutics 的持股增加了 12.5%。Virtus Investment Advisers LLC 目前持有 9,183 股該公司的股票，價值 95,000 美元，此前在此期間增持了 1,023 股。Marshall Wace LLP 在第二季度將其在 Cartesian Therapeutics 的持股增加了 114.0%。Marshall Wace LLP 目前持有 82,630 股該公司的股票，價值 859,000 美元，此前在此期間增持了 44,025 股。最後，683 Capital Management LLC 在第二季度將其在 Cartesian Therapeutics 的持股增加了 46.0%。683 Capital Management LLC 目前持有 219,000 股該公司的股票，價值 2,275,000 美元，此前在上個季度增持了 69,000 股。機構投資者和對沖基金持有該公司 86.95% 的股票。</p>
<h2>Cartesian Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Cartesian Therapeutics 在納斯達克以 RNAC 為交易代碼，是一家臨牀階段的生物技術公司，專注於基於信使 RNA（mRNA）治療的開發。該公司利用專有的 RNA 遞送平台，誘導患者體內產生治療性蛋白，旨在通過體內表達疾病修飾劑來解決一系列疾病。Cartesian 的技術旨在優化 mRNA 的穩定性、翻譯效率和靶向遞送，潛在應用涵蓋腫瘤學、自身免疫疾病和罕見遺傳病。</p>
<p>Cartesian 方法的核心是一個合成 mRNA 平台，結合了專有的脂質納米顆粒（LNP）配方。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好五隻股票而非 Cartesian Therapeutics</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>請勿刪除，立即閲讀</li>
<li>該股票獲得 94 分（滿分 100 分）</li>
<li>股票代碼揭曉：首次公開募股接入 “下一個 Elon Musk” 公司</li>
<li>自 2007 年以來首次：所有警告均已激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5BQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5BQw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Cartesian Therapeutics 嗎？</h2>
<p>在考慮投資 Cartesian Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Cartesian Therapeutics 並不在名單上。</p>
<p>雖然 Cartesian Therapeutics 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RNAC

<p>Needham & Company LLC 將 Cartesian Therapeutics (NASDAQ:RNAC) 的目標股價從 40.00 美元上調至 42.00 美元，維持 “買入” 評級。這表明從當前價格來看，潛在上漲幅度為 436.33%。其他分析師的看法不一，BTIG Research 將目標價上調至 44.00 美元，而 Wall Street Zen 則下調至 “賣出”。Cartesian 的股票目前交易價格為 7.83 美元，下跌 3.6%，市值為 2.0364 億美元。該公司報告季度每股虧損 1.38 美元，未能達到預期，收入為 45 萬美元</p>

<p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) had its price objective hoisted by investment analysts at Needham &amp; Company LLC from $40.00 to $42.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price target would suggest a potential upside of 436.33% from the company's current price.</p>
<div class="lb-trans"><p>Cartesian Therapeutics（納斯達克股票代碼：RNAC - 獲取免費報告）在週五向投資者發佈的一份報告中，投資分析師 Needham &amp; Company LLC 將其目標價格從 40.00 美元上調至 42.00 美元，Benzinga 報道。該券商目前對該股票給予 “買入” 評級。Needham &amp; Company LLC 的目標價格暗示該公司當前價格有 436.33% 的潛在上漲空間。</p>
</div><p>Get <strong>Cartesian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cartesian Therapeutics</strong> 的提醒：</p>
</div><p>Several other analysts have also recently weighed in on the stock. BTIG Research raised their price objective on shares of Cartesian Therapeutics from $42.00 to $44.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 14th. Wall Street Zen cut shares of Cartesian Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Cartesian Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright cut their price target on shares of Cartesian Therapeutics from $40.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, November 19th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $38.50.</p>
<div class="lb-trans"><p>其他幾位分析師最近也對該股票發表了看法。BTIG Research 在 11 月 14 日的研究報告中將 Cartesian Therapeutics 的目標價格從 42.00 美元上調至 44.00 美元，並給予該公司 “買入” 評級。華爾街 Zen 在 11 月 8 日的研究報告中將 Cartesian Therapeutics 的評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 12 月 29 日的報告中重申了對 Cartesian Therapeutics 的 “賣出（e+）” 評級。最後，HC Wainwright 在 11 月 19 日的報告中將 Cartesian Therapeutics 的目標價格從 40.00 美元下調至 30.00 美元，並對該股票給予 “買入” 評級。四位投資分析師對該股票給予 “買入” 評級，一位分析師對該公司給予 “賣出” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，平均目標價格為 38.50 美元。</p>
</div><p><strong>View Our Latest Report on RNAC</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 RNAC 的最新報告</strong></p>
</div><h2>Cartesian Therapeutics Stock Down 3.6%</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 股票下跌 3.6%</h2>
</div><p>Shares of NASDAQ:RNAC traded down $0.29 during midday trading on Friday, reaching $7.83. 42,503 shares of the company traded hands, compared to its average volume of 145,958. The firm's fifty day moving average price is $7.38 and its two-hundred day moving average price is $9.58. The firm has a market capitalization of $203.64 million, a price-to-earnings ratio of -5.07 and a beta of 0.38. Cartesian Therapeutics has a 12 month low of $5.98 and a 12 month high of $20.12.</p>
<div class="lb-trans"><p>在週五的午盤交易中，納斯達克：RNAC 的股票下跌 0.29 美元，報 7.83 美元。該公司交易了 42,503 股，而其平均交易量為 145,958 股。該公司的 50 日移動平均價格為 7.38 美元，200 日移動平均價格為 9.58 美元。該公司的市值為 2.0364 億美元，市盈率為-5.07，貝塔值為 0.38。Cartesian Therapeutics 的 12 個月低點為 5.98 美元，12 個月高點為 20.12 美元。</p>
</div><p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.57). The firm had revenue of $0.45 million during the quarter, compared to analysts' expectations of $0.18 million. Analysts forecast that Cartesian Therapeutics will post 4.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cartesian Therapeutics（納斯達克股票代碼：RNAC - 獲取免費報告）最後一次公佈季度財報是在 11 月 6 日。該公司報告本季度每股收益為（1.38 美元），低於市場共識預期的（0.81 美元）0.57 美元。該公司本季度的收入為 45 萬美元，而分析師預期為 18 萬美元。分析師預測 Cartesian Therapeutics 在當前年度的每股收益將為 4.56 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CFO Blaine Davis sold 10,591 shares of the firm's stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $6.82, for a total value of $72,230.62. Following the sale, the chief financial officer directly owned 121,220 shares in the company, valued at approximately $826,720.40. This trade represents a 8.03% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 60.30% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Blaine Davis 在 1 月 6 日的交易中出售了 10,591 股該公司的股票。股票以平均價格 6.82 美元出售，總價值為 72,230.62 美元。出售後，首席財務官直接持有該公司 121,220 股股票，估值約為 826,720.40 美元。這筆交易代表其持股比例下降了 8.03%。該交易已在證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。60.30% 的股票目前由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of RNAC. Rhumbline Advisers boosted its position in Cartesian Therapeutics by 27.5% during the first quarter. Rhumbline Advisers now owns 13,006 shares of the company's stock worth $171,000 after acquiring an additional 2,805 shares during the last quarter. Miller Financial Services LLC purchased a new stake in Cartesian Therapeutics in the second quarter valued at approximately $121,000. Virtus Investment Advisers LLC boosted its position in shares of Cartesian Therapeutics by 12.5% during the second quarter. Virtus Investment Advisers LLC now owns 9,183 shares of the company's stock worth $95,000 after buying an additional 1,023 shares during the period. Marshall Wace LLP increased its stake in Cartesian Therapeutics by 114.0% during the second quarter. Marshall Wace LLP now owns 82,630 shares of the company's stock worth $859,000 after purchasing an additional 44,025 shares during the period. Finally, 683 Capital Management LLC grew its stake in shares of Cartesian Therapeutics by 46.0% in the second quarter. 683 Capital Management LLC now owns 219,000 shares of the company's stock worth $2,275,000 after acquiring an additional 69,000 shares in the last quarter. Institutional investors and hedge funds own 86.95% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對 RNAC 的持股。Rhumbline Advisers 在第一季度將其在 Cartesian Therapeutics 的持股增加了 27.5%。Rhumbline Advisers 目前持有 13,006 股該公司的股票，價值 171,000 美元，此前在上個季度增持了 2,805 股。Miller Financial Services LLC 在第二季度購買了價值約 121,000 美元的 Cartesian Therapeutics 新股份。Virtus Investment Advisers LLC 在第二季度將其在 Cartesian Therapeutics 的持股增加了 12.5%。Virtus Investment Advisers LLC 目前持有 9,183 股該公司的股票，價值 95,000 美元，此前在此期間增持了 1,023 股。Marshall Wace LLP 在第二季度將其在 Cartesian Therapeutics 的持股增加了 114.0%。Marshall Wace LLP 目前持有 82,630 股該公司的股票，價值 859,000 美元，此前在此期間增持了 44,025 股。最後，683 Capital Management LLC 在第二季度將其在 Cartesian Therapeutics 的持股增加了 46.0%。683 Capital Management LLC 目前持有 219,000 股該公司的股票，價值 2,275,000 美元，此前在上個季度增持了 69,000 股。機構投資者和對沖基金持有該公司 86.95% 的股票。</p>
</div><h2>Cartesian Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian's technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.</p>
<div class="lb-trans"><p>Cartesian Therapeutics 在納斯達克以 RNAC 為交易代碼，是一家臨牀階段的生物技術公司，專注於基於信使 RNA（mRNA）治療的開發。該公司利用專有的 RNA 遞送平台，誘導患者體內產生治療性蛋白，旨在通過體內表達疾病修飾劑來解決一系列疾病。Cartesian 的技術旨在優化 mRNA 的穩定性、翻譯效率和靶向遞送，潛在應用涵蓋腫瘤學、自身免疫疾病和罕見遺傳病。</p>
</div><p>At the core of Cartesian's approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.</p>
<div class="lb-trans"><p>Cartesian 方法的核心是一個合成 mRNA 平台，結合了專有的脂質納米顆粒（LNP）配方。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Cartesian Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>This stock gets a 94 out of 100</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>First Time Since 2007: All Warnings Active</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好五隻股票而非 Cartesian Therapeutics</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>請勿刪除，立即閲讀</li>
<li>該股票獲得 94 分（滿分 100 分）</li>
<li>股票代碼揭曉：首次公開募股接入 “下一個 Elon Musk” 公司</li>
<li>自 2007 年以來首次：所有警告均已激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5BQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RNAC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cartesian Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Cartesian Therapeutics 嗎？</h2>
</div><p>Before you consider Cartesian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Cartesian Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Cartesian Therapeutics 並不在名單上。</p>
</div><p>While Cartesian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cartesian Therapeutics 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cartesian Therapeutics（NASDAQ:RNAC）被 Needham & Company LLC 設定了新的目標價為 42.00 美元